S.А. VAKHITOVA¹, N.А. TSIBULKIN², L.А. YAGUDINA²

¹Mendeleevsk Central Regional Hospital, 7 Severnaya Str., Mendeleevsk, Russian Federation, 423650

²Kazan State Medical Academy, 36 Butlerov Str., Каzan, Russian Federation, 420012

Vakhitova S.A. ― clinical laboratory diagnostician, tel. +7-917-856-50-35, e-mail: sveta.vakhitova.67@mail.ru

Tsibulkin N.A. ― Cand. Med. Sc., Associate Professor of the Department of Cardiology, Roentgenendovascular and Cardiovascular Surgery, tel. (843) 261-74-11, e-mail: kldkgma@mail.ru

Yagudina L.A. ― Cand. Med. Sc., Associate Professor of the Department of Clinical Laboratory Diagnostics, tel. +7-960-047-88-99, e-mail: yagudinaleila@mail.ru

 Diseases of prostate gland are frequent forms of pathology in males. For screening of these diseases, assessment of the level of prostate-specific antigen (PSA) in blood serum is used. Comparative studying of diagnostic efficiency of PSA test, which is carried out at planned medical examination or by indication of urologist, is of practical interest. The analysis of clinical application of PSA test during three years has shown that its efficiency as a screening method at planned medical examination remains low, being inferior to testing by indication of urologist. However, the higher total number of revealed persons with increased PSA level and the higher efficiency of the test in some age groups indicate the need to use it at planned medical examination. The PSA test may be used in both directions since any of them hasn’t shown superiority over another by all estimated indicators.

Key words: prostate gland, prostate-specific antigen, laboratory diagnostics.

REFERENCES

1. Sergeeva N.S., Marshutina N.V. General ideas about serological biomarkers and their place in oncology. Prakticheskaya onkologiya, 2011, vol. 12, no. 4, pp. 147-153 (in Russ.).
2. Matveev B.P. Klinicheskaya onkourologiya [Clinical oncourology]. ABV-Press, 2011.
3. Nilsson J., Skog J., Nordstrend A. et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. British journal of cancer, 2009, no. 100, pp. 1603-1607.
4. Lynn H., Hayes D. Cancer biomarkers. Molecular oncology, 2012, no. 6, rr. 140-146.
5. Zaenker P., Ziman M.R. Serologic autoantibodies as diagnostic cancer biomarkers – a review. Cancer epidemiology, biomarkers and prevention, 2013, no. 22 (12), pp. 1-21.
6. Instruktsiya po primeneniyu nabora reagentov dlya kolichestvennogo immunofermentnogo opredeleniya obshchego prostatspetsificheskogo antigena v syvorotke krovi cheloveka “OnkoIFA-obshchiy PSA” [Instructions for the use of a reagent kit for quantitative immunoenzymatic determination of the total prostate-specific antigen in human serum «Onco-IFA-total PSA»]. “Alkor Bio”, 2015.
7. Kishkun A.A. Sovremennaya klinicheskaya laboratornaya diagnostika [Modern clinical laboratory diagnostics]. Moscow: Assotsiatsiya nezavisimykh kliniko-diagnosticheskikh laboratoriy, 2014.